三阴性乳腺癌靶向治疗进展

三阴性乳腺癌(triple-negative breast cancer,TNBC)是雌、孕激素受体和HER-2表达均为阴性的乳腺癌,侵袭性强,与其他分子分型乳腺癌相比复发率较高,生存率低。临床上内科治疗主要以化疗为主,随着对TNBC分子分型的深入探索,靶向治疗的研究逐渐成为关注的焦点。近些年,多种靶向药物进入临床试验,取得一定疗效,不良反应相对较轻,部分药物已批准上市。本文将对TNBC的靶向治疗应用进展进行综述。

Advances in targeted therapy for triple-negative breast cancer

Triple negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer that is characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2), thereby making it difficult to treat. Owing to the aggressive clinical behavior of TNBC and the lack of recognized molecular targets for therapy, patients with TNBC have shown poorer outcomes than those with other subtypes of breast cancer. Chemotherapy is the primary established systemic treatment for TNBC. However, various novel therapeutic targets have come into focus with the advances in molecular characterization of TNBC. In recent years, several targeted drugs have undergone clinical trials and have shown certain curative effects with relatively mild adverse reactions. The Food and Drug Administration has approved some of these drugs. In the current review, we have summarized the advances in the targeted therapy of TNBC.